Living Without Blockbusters

Herper, Matthew
November 2009
Forbes Asia;11/16/2009, Vol. 5 Issue 17, p82
The article discusses the plans of Christopher Viehbacher, chief of drug company Sanofi Aventis Ltd., to reduce expenditure on research and to move into markets of emerging countries. He formed committee of experts on diabetes and tumors to face the drug safety police. Viehbacher can achieve his revenue goals by giving patent protection on established drugs. Sanofi research laboratories manufactured a vaccine for dengue fever, which is being tested in 4,000 children in Thailand.


Related Articles

  • A Focus on Emerging Markets. Van Arnum, Patricia // Pharmaceutical Technology;Mar2011, Vol. 35 Issue 3, p70 

    The article focuses on the strength of emerging markets that is reflected in sales and production positions of the pharmaceutical industry around the world. According to IMS Health Inc., the value of the global pharmaceutical market is expected to grow 5%-7% to 880 billion dollars in 2011. The...

  • FRENCH REVOLUTION. ARMSTRONG, WALTER // Pharmaceutical Executive;Jul2009, Vol. 29 Issue 7, p34 

    The article reports on the profits earned by the French pharmaceutical firm Sanofi-Aventis SA during 2008-2009. The companies shares gained 9.8% in 2008. Chris Viehbacher was appointed as the new chief executive officer (CEO) of the company on December 1, 2008, who reportedly established Sanofi...

  • Christopher A Viehbacher resigns as Sanofi's CEO.  // Express Pharma;07/16/2014, p2 

    The article announces that Christopher A. Viehbacher has resigned as a director of Sanofi-Aventis SA as he was unanimously removed by the Board of Directors as the chief executive officer of the company.

  • Sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011.  // Biomedical Market Newsletter;5/5/2011, p617 

    The article offers information on the financial performance of Sanofi-Aventis SA for the first quarter (Q1) of 2011 in Paris, France. The company experienced strong growth in Q1 with a consolidation net income of 1,218 million euro. Sanofi's chief executive officer Christopher A. Viehbacher is...

  • SANOFI-AVENTIS TO ACQUIRE BIPAR SCIENCES.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p4 

    This article reports on an agreement signed by Sanofi-aventis for the acquisition of BiPar Sciences Inc. in 2009. According to Hoyoung Huh, president and chief executive officer (CEO) of BiPar Sciences, the agreement validates BiPar's novel scientific approach and will maximize patient access to...

  • Another Genzyme Rejection as Sanofi Bid Really Gets 'Hostile.'. Boggs, Jennifer // BioWorld Today;10/11/2010, Vol. 21 Issue 196, p1 

    The article reports on the decision by the board of Genzyme Corp. to reject again the 69 U.S. dollar-per-share takeover offer made by Sanofi-Aventis SA. A meeting is said to have been conducted by top executives during which Sanofi Chief Executive Officer (CEO) Chris Viehbacher allegedly...

  • Genzyme-Sanofi buyout is second largest biotech deal ever. Ratner, Mark // Nature Biotechnology;Apr2011, Vol. 29 Issue 4, p293 

    The article discusses the buyout by Sanofi-aventis of Paris, France of Massachusetts-based Genzyme. The takeover negotiations started in late July 2010 when Sanofi presented a 17.5 billion U.S. dollars offer to Genzyme management which was rejected due to Sanofi's failure to recognize Genzyme's...

  • SANOFI-AVENTIS LAUNCHED. Arnold, Matthew // Medical Marketing & Media;Jun2009, Vol. 44 Issue 6, p9 

    The article reports on the launch of the Sanofi-Aventis SA of its web TV site, sanofi-aventis.tv. It mentions that the site features interviews of executives, information about various diseases and corporate manifesto. Sanofi-Aventis chief executive officer Chris Viebacher notes that the...

  • COMPANY SPOTLIGHT - Sanofi-Aventis Group.  // PharmaWatch: Cancer;Jan2006, Vol. 5 Issue 1, p21 

    The article presents information about the pharmaceutical company Sanofi-Aventis SA. The company specializes in cardiovascular, thrombosis, metabolic disorders, oncology, central nervous system, internal medicine and vaccines. The company's six largest-selling pharmaceutical products account for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics